Participated · Series C · Jun 2026

Cadence Solutions builds Clinical Intelligence that monitors patients with chronic disease, surfaces risks, and coordinates actions through supervised AI agents integrated into health systems' EMRs and workflows. The company works alongside more than 20 leading health systems and currently treats over 100,000 active patients. Peer-reviewed studies and real-world deployments cited in the company's materials show validated outcomes, including a 230% increase in heart-failure patients on guideline-directed medical therapy, a 70% relative increase in blood-pressure control for hypertension patients, a 27% reduction in hospital admissions, and a $1,302 per-patient annual reduction in total cost of care. Cadence reported it saves Medicare roughly $2.7 million every week and that its model returns more than $3 to Medicare for every dollar spent. Commercial traction includes tripling annual recurring revenue in 2025 and new affiliations with Duke Health and Texas Health Resources. With the Series C capital, Cadence plans to accelerate expansion into additional health systems, further develop its AI agents, and scale value-based care deployments.

Participated · Series B · Sep 2025

Founded in 2019, AmplifyMD offers health systems a cloud-based, EHR-integrated virtual care platform paired with a national physician network spanning more than 15 specialties. Its AI-driven workflows surface relevant patient data at the point of care and intelligently route consults, allowing physicians to cover multiple sites and departments efficiently. The solution underpins over 300 hospital and outpatient programs and has delivered measured results such as a 52% reduction in TeleStroke operating costs, a two-fold increase in TeleHospitalist consult volume per shift, and the shortening of outpatient specialty wait times from months to days. Health systems use the platform to improve clinical access, reduce patient transfers, and bolster revenue cycle performance while alleviating staffing pressures. With its newly raised capital, AmplifyMD plans to deepen AI and workflow capabilities and broaden strategic partnerships to make virtual coverage a sustainable advantage for hospitals. The company’s traction and outcome data position it as a leading enabler of scalable, high-quality virtual care across the United States.

Participated · Series A · Sep 2025

Optain Health offers a portable robotic retinal camera, integrated AI workflows, and teleophthalmology to enable rapid, non‑invasive screening for eye diseases and systemic risk (oculomics). Its platform detects diabetic retinopathy, glaucoma, age‑related macular degeneration, and assesses cardiovascular risk while delivering teleophthalmology grading in the U.S. The company was co‑created in 2023 by Aegis Ventures and builds on more than a decade of Australian R&D led by Professor Mingguang He. Optain is expanding deployments into primary care, optometry, and health systems with the goal of closing care gaps and improving outcomes with minimal specialist staffing. The company uses teleophthalmology services in the U.S.; its automated disease detection software is not for sale in the U.S. Optain is scaling globally with investments in Australian R&D to support expansion outside the U.S. Optain develops AI-enabled software and hardware that noninvasively diagnose eye and systemic health conditions in real time using photos of the eye. Its portable retinal camera and accompanying AI software enable clinicians to screen for more than 140 eye and systemic conditions at early stages. The company is led by CEO Jeff Dunkel and positions the eye as a gateway to monitor whole-person health. Optain's approach is based on over a decade of research by Professor Mingguang He of the University of Melbourne and the Centre for Eye Research Australia. The company traces its roots to Australian-founded Eyetelligence (launched in 2019), whose clinically validated and regulatory-approved AI products are commercialized across Australia, New Zealand, Europe, Japan and the Middle East. Optain intends to use recent seed funding to expand operations and development efforts.

Led · Series C · May 2025

Rad AI develops generative AI products for radiology, including Rad AI Impressions, Rad AI Reporting, and Rad AI Continuity, that are embedded into radiologists' workflows. Its Impressions product automates the impression section and saves radiologists more than an hour per shift on average. Rad AI Reporting includes features such as Omni Unchanged and Omni Report, which cut follow-up dictation time by 50%, reduce spoken words by 90%, and can double reporting speed. Rad AI Continuity automates tracking and coordination of incidental findings and has improved follow-up exam completion rates from approximately 30% to over 75% at users. The platform is trusted by thousands of U.S. radiologists and supports providers responsible for nearly half of all imaging volume in the U.S. The company is scaling enterprise deployments across hospitals and clinics with health-system partners to expand adoption and improve care coordination and efficiency. Rad AI develops generative AI solutions for radiology including Rad AI Impressions, Rad AI Reporting, and Rad AI Continuity that automate draft report text, reduce dictated words, and close the loop on actionable findings. Its flagship Rad AI Reporting can reduce dictated words by up to 90% and save providers up to 50% of their time; Rad AI Continuity has raised follow-up rates at health systems from about 30% to 75% or more. The company's products are used by thousands of U.S. radiologists daily and are deployed at health systems and practices that account for nearly 50% of U.S. medical imaging. Rad AI says it was the first to commercialize a generative AI product in healthcare and has been recognized by CB Insights and AuntMinnie for its products. The company is hiring across roles and plans to accelerate development and deployment of its generative AI technology to healthcare providers and systems globally. Rad AI builds software that generates radiology reports, aiming to cut the time radiologists spend on documentation. The company developed a proprietary LLM trained on radiology report datasets to automate findings and impressions. Rad AI says it began using LLMs in 2018 and positions itself as an early adopter of generative AI in radiology. Its products are used by about a third of U.S. health systems and nine of the 10 largest radiology groups. The company has raised over $80 million in total capital after a $50M Series B and plans to use the fresh funding to build a team to deploy a standalone radiology reporting solution. Rad AI is hiring staff to install and maintain the software and reports it has not lost a single customer since launch. Rad AI provides an AI platform that automatically generates customized impressions from dictated findings and clinical indications, learning each radiologist’s language preferences from prior reports. Its core offerings, Rad AI Omni and Rad AI Continuity, aim to improve report accuracy and consistency, surface significant incidental findings, and provide guideline-based follow-up recommendations. Omni injects the impression directly into the practice’s voice recognition software without extra clicks or windows, while Continuity closes the loop on follow-up by integrating into health systems’ EMRs and offering an outpatient platform. The company emphasizes time savings for radiologists, improved report processes, and reduced burnout. Rad AI is working with seven of the ten largest private radiology practices in the U.S. and plans to use new funding to further develop and commercialize its products. Rad AI, founded in 2018 by Doktor Gurson and Dr. Jeff Chang in Berkeley, Calif., builds machine-learning tools to automate repetitive radiology tasks. Its first product automatically generates the impression section of radiology reports, customized to each radiologist's preferred language. The company raised $4M in seed funding to build out its engineering team and expand the rollout of its first product to more radiology groups and customers. The round was led by Gradient Ventures, with participation from UP2398, Precursor Ventures, GMO Venture Partners, Array Ventures, Hike Ventures, Fifty Years VC and various angels. Current partners include Greensboro Radiology, Medford Radiology, Einstein Healthcare Network and Bay Imaging Consultants, along with other radiology groups yet to be announced.

Participated · Series B · May 2025

Carta Healthcare provides an AI-powered platform that automates clinical data abstraction and analytics, combining machine learning with deep clinical expertise to extract and structure both structured and unstructured clinical data. Its technology generates actionable insights for health systems and life sciences organizations, streamlining data abstraction processes and reducing labor costs. The company plans to expand its customer footprint—particularly in the life sciences market—and to scale product deployment and operations following its late-2024 acquisition of Realyze Intelligence from UPMC Enterprises. The Realyze Intelligence acquisition added capabilities for rapidly analyzing data and identifying patients who match clinical trials and research studies. Founded in 2017 and headquartered in San Francisco, Carta reports consistent year-over-year growth and says the new capital will support hiring, infrastructure, and expanded market demand. The company’s CFO described Carta as financially healthy and positioned to strengthen its balance sheet and capture market opportunity. Carta Healthcare delivers collection, analysis, and insights into clinical data by providing registry data abstraction, reporting, and analytics to leading health systems. The company combines state-of-the-art technology with a team of experienced clinicians to produce high-quality registry data and associated analytics. By transforming the abstraction process and implementing powerful analytic capabilities, Carta informs data-driven decisions that can improve patient outcomes, reduce data-processing costs, and enable clinicians to spend more time on patient care. The company reports markedly faster data collection, superior data quality, and considerable cost savings for healthcare providers. Carta intends to use the recent funding to scale operations and accelerate product development to make more products accessible to more health systems. The business is focused on enhancing healthcare data processes and analytics to support better patient outcomes and research capabilities. Carta Healthcare provides AI-driven clinical data abstraction technology and services that use natural language processing and machine learning to reduce manual labor in curating trustworthy, actionable datasets. Its platform collects, analyzes, and layers analytic capabilities on clinical data to fuel data-driven healthcare decisions and improve patient care. The company supports the healthcare data registry market by transforming previously manual abstraction processes into automated workflows. Carta plans to use new funding to expand its clinical and technical teams and build new partnerships to make healthcare data more actionable. The company emphasizes making data-driven improvements to care delivery and bringing its solutions to new partners. Carta was founded in 2017 and is headquartered in San Francisco; it announced a recent Series A to accelerate growth.